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Abstract. The influence of formulation variables, i.e., a hydrophilic polymer (Methocel® E15) and a film-
forming polymer (Eudragit® RL 100 and Eudragit® RS 100), on the physicochemical and functional
properties of a transdermal film formulation was assessed. Several terpenes were initially evaluated for
their drug permeation enhancement effects on the transdermal film formulations. D-Limonene was found
to be the most efficient permeation enhancer among the tested terpenes. Transdermal film formulations
containing granisetron (GRN) as a model drug, D-limonene as a permeation enhancer, and different ratios
of a hydrophilic polymer (Methocel® E15) and a film-forming polymer (Eudragit® RL 100 or Eudragit®
RS 100) were prepared. The prepared films were evaluated for their physicochemical properties such as
weight variation, thickness, tensile strength, folding endurance, elongation (%), flatness, moisture content,
moisture uptake, and the drug content uniformity. The films were also evaluated for the in vitro drug
release and ex vivo drug permeation. The increasing ratios of Methocel®:Eudragit® polymers in the
formulation linearly and significantly increased the moisture content, moisture uptake, water vapor
transmission rate (WVTR), and the transdermal flux of GRN from the film formulations. Increasing
levels of Methocel® in the formulations also increased the rate and extent of the GRN release and the
GRN permeation from the prepared films.
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INTRODUCTION
The transdermal drug delivery can no longer be consid-
ered a Bnovel^ drug delivery technology. Over the past few
decades, there has been a tremendous growth in the under-
standing of the technology involved in the development of
transdermal drug delivery systems (TDDS). TDDS are de-
signed to deliver the drug(s) across the skin at a controlled
rate into the systemic circulation. TDDS offers several, well-
documented advantages over the conventional oral and par-
enteral routes of drug delivery (1–3). These include therapeu-
tic advantages such as sustained delivery of drugs, avoiding
pre-systemic metabolism, avoiding hostile gastrointestinal fac-
tors (e.g., gastric pH, gastric transit time, etc.), suitability for
drugs with short biological half-life and narrow therapeutic
index, and relatively lower fluctuations observed in the drug
plasma levels. Some of the patient compliance benefits include
non-invasive drug administration, flexibility in the dosing fre-
quency, suitability for self-medication, and better control of
the side effects/adverse effects. TDDS are also associated with
uncommon limitations such as suitability limited to potent
(low dose) drugs, stratum corneum as a barrier to drug ab-
sorption, requirement of the ideal permeability characteristics
of the drugs, non-suitability for tolerance-inducing drugs, and
costly nature of the dosage form (1,4,5). Nevertheless, several
transdermal formulations consisting of drugs over a range of
pharmacological classes are approved to be marketed in the
USA or are in different stages of development (4,5). The
TDDS market is reported to be worth $12.7 billion in 2005
and is anticipated to be over $30 billion this year (2015) (4).
Stratum corneum, being a natural protector, limits the
penetration of the xenobiotics. It is known to be a major
rate-limiting factor to the transdermal absorption of a drug
and its subsequent systemic bioavailability (6). The role of
permeation enhancers in the formulation of transdermal sys-
tems was envisaged early on to overcome the challenge of
limited transdermal absorption of a drug (7,8). Permeation
enhancers originating from a wide variety of chemical classes,
including alcohols, fatty acids, amines, esters, amides, hydro-
carbons, surfactants, etc., have been explored to enhance the
transdermal absorption of the drugs (9). The permeation en-
hancers act mainly by disrupting the lipid bilayers within the
stratum corneum (10). The disruption of the natural integrity
of the stratum corneum is known to cause skin irritation, and
thus, a rational selection of a permeation enhancer that en-
hances the drug permeation through the skin with minimal
alteration of the structure and functions of the skin is of
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critical importance (11). Terpenes are naturally occurring vol-
atile oils that have gained popularity in the recent years as
choice enhancers in transdermal formulations (12). Terpenes
are also known to be versatile in their applications, i.e., they
are suitable for the percutaneous penetration and absorption
enhancement of both hydrophilic and lipophilic drugs (13,14).
Moreover, compared with surfactants and other permeation
enhancers, terpenes, when used in lower concentrations, ex-
hibit relatively lower percutaneous irritancy (15).
Other key components of transdermal formulations
apart from the permeation enhancers include the film-
forming polymers and one or more hydrophilic polymers
incorporated as rate-controlling matrix formers (16–18).
These excipients are available in a wide range of physico-
chemical properties and grades. The nature and the
amount of these excipients incorporated in a TDDS can
have a significant influence on the manufacturability, qual-
ity, and performance of the final drug product. Most of
the studies report the incorporation of a variety of these
excipients in the formulation of transdermal delivery sys-
tems (19–21). However, the studies that evaluate the in-
fluence of these formulation variables in a systematic,
quantitative manner are few and far between.
The present investigation was aimed at quantitatively
and systematically assessing the influence of the ratio of
two formulation variables, i.e., a hydrophilic polymer and
a film-forming polymer, on the physicochemical and func-
tional attributes of transdermal films. The study was car-
ried out in three stages. First, several terpenes were
evaluated for their permeation-enhancing efficiency across
the excised hairless rat skin. Granisetron (GRN) was cho-
sen as a model drug for this study. The physicochemical
properties of GRN allow it to be incorporated into a
transdermal drug delivery system. These properties in-
clude low molecular mass, high lipid solubility, low thera-
peutic dose, as well as a high degree of first-pass
metabolism. Next, several transdermal film formulations
containing different ratios of a hydrophilic polymer
(Methocel® E15) and a film-forming polymer (Eudragit®
RL 100 or Eudragit® RS 100) were prepared. Finally, the
prepared films were evaluated for their physical, chemical,
in vitro drug release, and ex vivo drug permeation
properties. The results were statistically analyzed to
understand the influence of these formulation variables
on the prepared films.
MATERIALS AND METHODS
Materials
Granisetron samples were obtained from Wockhardt
Limited (India). Hydroxypropyl methycellulose (Methocel®
E15) was obtained from Colorcon Asia Pvt. Ltd. (India).
Eudragit® RL 100 and Eudragit® RS 100 were obtained
from Evonik Degussa India Pvt. Ltd. (India). Eugenol and
D-limonene were obtained from Keva Fragrances Ltd. (India).
α-Terpineol and menthol were obtained from Workwell
(India). ScotchPak™ 1109 backing membrane was obtained
from 3M Drug Delivery Systems, USA. Other solvents and
reagents used were of analytical grade.
Methods
Preparation of Biological Membrane for Permeability Studies
Ethical clearance for the handling of experimental ani-
mals was obtained from the institutional animal ethics com-
mittee (IAEC) formed for this purpose. Male Sprague
Dawley® rats weighing 200 to 250 g were euthanized by
cervical dislocation, and the dorsal skin was removed. After
removing the epidermal hair and the subcutaneous fat, the
skin was thoroughly washed with phosphate-buffered saline
(PBS, pH 7.4) and placed overnight in contact with the recep-
tor phase, i.e., fresh PBS, pH 7.4. The overnight-stored rat skin
was used for ex vivo permeability studies.
Effect of Penetration Enhancers on Permeation of Granisetron
The ex vivo permeation studies were carried out in a Franz
diffusion cell with a diffusion surface area of 2.5 cm2. The
biological membrane, with the stratum corneum facing the
donor segment, was affixed to the diffusion cell. GRN solution
(1 mg/ml, in PBS, pH 7.4) was placed in the donor compartment
containing D-limonene (5% v/v), α-terpineol (5% v/v), eugenol
(5% v/v), or menthol (5% v/v). The absence of penetration
enhancer served as a control. The receiver compartment
contained magnetically stirred PBS (18 ml, pH 7.4), maintained
at 37±0.5°C. The amount of drug permeated through the biolog-
ical membrane was determined by analyzing the drug concentra-
tion in the filtered samples (1 ml), withdrawn at predetermined
time intervals. The samples were analyzed using a modified
reverse-phase HPLC at a wavelength of 305 nm. The cumulative
amount (%) of drug permeated was plotted against time.
Permeation Data Analysis
The drug concentration in the permeate was corrected for
sampling effects according to the equation described by
Hayton et al. (Eq. (1)) (22):
C
0
n ¼ Cn
VT
VT−Vs
 
C
0
n−1
Cn−1
 !
ð1Þ
where C
0
n is the corrected concentration of the nth sample, Cn
is the measured concentration of GRN in the nth sample, Cn1
is the measured concentration of the GRN in the (n−1)th
sample, VT is the total volume of the receiver fluid, and Vs is
the volume of the sample drawn. The steady-state flux (Jss)
and the permeability coefficient (Kp) were calculated using
Eqs. (2) and (3), respectively, as described by Barry (23):
Jss ¼ dQdt
 
ss
 1
A
ð2Þ
Kp ¼ JssCs ð3Þ
where A is the effective diffusion area, Cs is the concentration
in the saturated solution, and dQdt
 
ss is the steady-state slope.
The penetration-enhancing effect of the terpenes was
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calculated as enhancement ratio (ER), using the following
equation (Eq. (4)) (12):
ER ¼ KP with penetration enhancerð Þ
KP without penetration enhancerð Þ ð4Þ
Drug-Polymer Compatibility Studies
The preliminary physicochemical compatibility between
GRN and the polymers used in the films was evaluated using
differential scanning calorimetry (DSC) and the Fourier trans-
form infrared (FTIR) spectroscopy.
Differential Scanning Calorimetry. The thermal analysis
of GRN, the pure polymers, and their physical mixtures
with GRN was carried out using a differential scanning
calorimeter (Model: Q10, TA Instruments, Inc., New
Castle, DE, USA). The analysis was done under a purge
of dry nitrogen gas (50 ml/min). High-purity indium was
used to calibrate the heat flow and the heat capacity of
the instrument. The samples (2.5–5 mg) were sealed in
aluminum pans with the lids using a crimper. Each sam-
ple was subjected to a single heating cycle from 25 to
400°C at a heating rate of 10°C/min. The results were
analyzed using the Universal Analysis software version
4.5A, build 4.5.0.5 (TA Instruments, Inc., New Castle,
DE, USA).
Fourier Transform Infrared Spectroscopy. The infrared
spectra of GRN, the polymers, and their physical mix-
tures with GRN were obtained from an FTIR spectro-
photometer (Model: IR Prestige-21, Shimadzu, Japan)
equipped with an attenuated total reflectance (ATR) ac-
cessory. The analysis of the samples was carried out
using diffuse reflectance spectroscopy (DRS)-FTIR with
KBr. The influence of the residual moisture was theoret-
ically removed by subjecting the samples to vacuum dry-
ing before obtaining any spectra. Each sample analysis
included 45 scans, at a resolution of 4 cm−1 from 4000 to
600 cm−1.
Preparation and Characterization of Granisetron Transdermal
Films
As shown in the Table I, ten matrix-type transdermal
film formulations containing GRN, Methocel® E15, and
Eudragit® RL 100 or Eudragit® RS 100 were prepared.
The preparation method as described previously by
Kusum Devi et al. was followed (17). Briefly, the drug
and the polymers, propylene glycol (plasticizer), and D-
limonene (penetration enhancer) were dispersed in
ethanol (casting solvent), and the polymeric dispersion
was degassed by sonication. The polymeric dispersion of
the drug was then poured into a circular well formed by a
glass mold (5.68 cm2, fabricated in the laboratory for the
purpose), placed in a standard Petri dish containing
mercury (Fig. 1). The rate of solvent evaporation was
qualitatively controlled by covering the mold with an
inverted funnel. The dry films were obtained after the
evaporation of the casting solvent overnight in a solvent
hood. The dried formulation films were carefully cut into
uniform sizes to contain a theoretical equivalent of ∼4 mg
of the drug per film. This dose of GRN (4 mg per film)
was targeted based on the recommended therapeutic
doses of GRN for chemotherapy-induced nausea and
vomiting (24). Preliminary studies based on film dimen-
sions showed that GRN (9.1% w/w) in the formulations
achieved this target dose per film. A backing membrane
was attached to the prepared films, and the films were
stored in a desiccator, between the sheets of glassine
paper.
Evaluation of Physicochemical Properties of Films
Weight Variation. The weight variation of the prepared
films was evaluated by individually weighing three randomly
selected films of each prepared formulation. The mean weight
and the standard deviation for each formulation film were
calculated and recorded.
Thickness. The thickness of prepared films was measured
using a digital micrometer screw gauge with a least count of
0.001 mm (Mitutoyo, Japan) at three different locations on the
film. Three randomly selected films of each formulation were
evaluated for thickness. The mean thickness (mm) and the
standard deviation for each formulation film were calculated
and recorded.
Tensile Strength. The mechanical properties of the pre-
pared polymer films were determined by measuring their
tensile strength as described previously by Yener et al.
(25). According to the American Society for Testing and
Materials (ASTM), the tensile strength of polymeric films
is a measure of the minimum stretching force applied to
the sample that results in the breaking of the film. The
tensile strength measurements were carried out on
dumbbell-shaped films (2.5×1 cm). The formulation films
were subjected to a pulling force by hanging standard
weights from the films and measuring the force (kg/mm2)
using a load cell.
Percentage Elongation. The determination of longitudi-
nal strain (percentage elongation at break) was carried out as
described by Khanna et al. (26). The percentage elongation at
break for the film samples was calculated using the following
formula (Eq. (5)):
%elongation at break ¼ increase in length
initial length
 100 ð5Þ
Folding Endurance. The folding endurance was evalu-
ated by repeatedly folding a small strip of film (2.5 cm2)
at the same location to the point of breaking (17). The
folding endurance value is typically described as the
number of times a film may be folded at the same
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location before it breaks. Three randomly selected
samples of each prepared formulation film were
evaluated for the folding endurance. The mean and the
standard deviation for each formulation were calculated
and recorded.
Drug Content Uniformity. The GRN content was
assayed on ten randomly selected films from each formu-
lation. The prepared films were dissolved in ethanol
(2 ml), and the volume was adjusted to 100 ml with PBS
(pH 7.4). The solution was filtered and suitably diluted,
and the GRN content of each film was determined using a
modified reverse-phase HPLC (RP-HPLC) method previ-
ously described by Pinguet et al. (27). Briefly, the HPLC
system (Model: Prominence, Shimadzu Corporation,
Kyoto, Japan) with LCsolution software, equipped with a
LC-20AD HPLC pump, a manual rheodyne sample injec-
tor, and a SPD-M20A detector, was used. The mobile
phase was composed of methanol/0.02 M phosphate buffer
(pH 4.0) (40:60, v/v), at a flow rate of 1 ml/min. A
Hypersil-Keystone C-18 column (250×4.6 mm, 5 μm) was
used as a stationary phase, and the GRN samples were
detected by ultraviolet (UV) detection at 305 nm. The
calibration of the peak area against concentration of
GRN was found to be y=10,498x−73.42 with R2=0.9997
for the GRN concentration range of 2–10 μg/ml (where
y=peak area and x=GRN concentration), and the limit of
detection was found to be 0.02 μg/ml.
Flatness . A method prev ious ly descr ibed by
Kshirsagar et al. was used to calculate the flatness of the
prepared films (20). Briefly, the prepared films were cut
into uniform longitudinal strips. The length of each strip
was then measured accurately, and the variations in
length due to the non-uniformity of flatness were mea-
sured. The flatness of the strips was calculated by mea-
suring the percent constrict ion using Eq. (6). A
constriction value of 0% was assumed to indicate 100%
flatness. Three randomly selected films of each formula-
tion were evaluated for flatness. The mean and the stan-
dard deviation values for each formulation were calculated and
recorded:
%Constriction ¼ l1−l2
l2
 100 ð6Þ
Percent Moisture Content. Three randomly selected films
of each prepared formulation were marked, then weighed
individually, and placed in a desiccator at room temperature
(25±0.5°C). The films were then removed and weighed at
predetermined intervals until a constant weight was achieved.
The moisture content (%) was calculated as a difference
between the initial and the final weight with respect to the
final weight (Eq. (7)) (28). The mean and the standard devi-
ation values for each formulation were calculated and record-
ed.
% moisture content ¼ final wt:−initial wt:
initial wt:
 100 ð7Þ
Percentage Moisture Uptake. The physical stability and
the integrity of the polymeric films in humid environments
Table I. Composition of the Transdermal Films
Formulation
Composition (% w/w)
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
Granisetron 9.1 9.1 9.1 9.1 9.1 9.1 9.1 9.1 9.1 9.1
Methocel® E15 72.7 54.5 45.5 36.4 18.2 72.7 54.5 45.5 36.4 18.2
Eudragit® RL 100 18.2 36.4 45.5 54.5 72.7 0.0 0.0 0.0 0.0 0.0
Eudragit® RS 100 0.0 0.0 0.0 0.0 0.0 18.2 36.4 45.5 54.5 72.7
Propylene glycola 25.0 25.0 25.0 25.0 25.0 25.0 25.0 25.0 25.0 25.0
D-Limoneneb 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0
aQuantity represents % w/w of the total polymer weight
bQuantity represents % w/w of the total polymer weight
Fig. 1. Preparation of GRN films. a Circular glass mold in a Petri dish filled with mercury, b Mold covered
with an inverted funnel to qualitatively control solvent evaporation, and c Dried GRN film
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are typically evaluated by calculating the percent moisture
absorption at elevated humidity conditions.
The extent of moisture uptake by the prepared films
at elevated humidities and at room temperature (25±
0.5°C) was determined using the method described by
Kusum Devi et al. (17). Briefly, saturated solutions of
ammonium dihydrogen phosphate (60±5% RH), sodium
chloride (75±5% RH), and potassium nitrate (90±5%
RH) were placed in three separate desiccators respectively
and allowed to equilibrate for 24 h to attain the respective
humidity values (29). Three randomly selected films from
each formulation were weighed and placed in each desic-
cator. The films were then removed at predetermined in-
tervals and carefully weighed, until a constant weight was
achieved (17). The percentage moisture uptake by the
films was calculated using Eq. (8):
% moisure uptake ¼ final wt:−initial wt:
initial wt:
 100 ð8Þ
Water Vapor Transmission Rate. The water vapor trans-
mission rate (WVTR) is the amount of moisture transmitted
through a unit area of film in a given duration at room tem-
perature (25±0.5°C). The WVTR for the prepared films was
calculated using a method reported earlier (17). Briefly, glass
cells were filled with 2 g of anhydrous calcium chloride, and a
formulation film of specified area was affixed onto the cell rim.
The cells were accurately weighed and placed in desiccators
containing saturated solutions of ammonium dihydrogen
phosphate (60±5% RH), sodium chloride (75±5% RH), or
potassium nitrate (90±5% RH), respectively (29). The glass
cells were removed from the desiccators at regular intervals
and weighed accurately. The process was continued until a
constant weight was achieved. The amount of water vapor
transmitted was determined using the formula below
(Eq. (9)):
WVTR ¼ final weight−initial weight
area time ð9Þ
In Vitro Release Studies
The in vitro release of GRN from the prepared formula-
tion films was determined using a Franz diffusion cell. Three
randomly selected films of each formulation were used for the
analysis of drug release from the prepared films. The film,
supported with a backing membrane, was placed in the donor
compartment of the cell. The donor compartment was sepa-
rated from the receptor compartment by a dialysis membrane
(Himedia®), with a molecular weight cutoff between 12,000
and 14,000. The dialysis membrane was previously stored in
PBS (pH 7.4) for 24 h. The receptor compartment contained
magnetically stirred PBS (18 ml, pH 7.4) maintained at 37±
0.5°C. The amount of GRN released was determined by
analyzing the drug concentration in the filtered samples
(1 ml), withdrawn at predetermined time intervals. The
samples were analyzed using a modified RP-HPLC at a wave-
length of 305 nm. The cumulative drug release (%) was cal-
culated and plotted against time.
Ex Vivo Permeation Studies
The ex vivo permeation studies were carried out
using a Franz diffusion cell mounted with excised rat skin,
with the stratum corneum facing the donor compartment.
The drug-releasing surface of the transdermal film under
evaluation was placed in contact with the stratum
corneum side of the skin. The receiver compartment
contained magnetically stirred PBS (18 ml, pH 7.4), main-
tained at 37±0.5°C. The amount of GRN permeated was
determined by analyzing the drug concentration in the
filtered samples (1 ml), withdrawn at predetermined time
intervals. The samples were analyzed using a modified
RP-HPLC at a wavelength of 305 nm. The cumulative
GRN permeated (%) was calculated and plotted against
time.
The target flux was calculated using the equation de-
scribed previously by Suwanpidokkul et al. (Eq. (10)) (30):
Jtarget ¼ CSSCltBWA ð10Þ
whereA represents the surface area of the transdermal film (i.e.,
2.5 cm2); BW, the standard human body weight of 60 kg;CSS, the
GRN concentration at the therapeutic level (3.07 μg/l); and Clt,
the total clearance (0.52 l/h). The calculated target flux value for
GRN was 42.57 μg/h/cm2.
Statistical Analysis
The statistical analysis was carried out by a two-way
analysis of variance (ANOVA), followed by Bonferroni
post-test using GraphPad® Prism® software version 5.03
(San Diego, CA). The results were expressed as mean±
standard deviation (SD). The differences between the
means were considered to be significant if the P value
was <0.05.
RESULTS
Effect of Penetration Enhancers on the Permeation
of Granisetron
The influence of selected terpenes on the cumulative
permeation of GRN through rat skin is shown in Fig. 2. The
penetration-enhancing efficiency of these terpenes was found
to be in the order D-limonene (90%)>α-terpineol (72%)>
eugenol (60%)>menthol (48%). All tested terpenes demon-
strated a significant (P<0.05) improvement in the permeation
of GRN across the rat skin compared with the control (22%)
at the end of 24 h. These results are in agreement with those
reported previously.
The calculated transdermal flux values of GRN obtained
with D-limonene, α-terpineol, eugenol, and menthol were
found to be 33.37±2.16, 26.70±0.84, 22.25±1.58, and 17.80±
1.05 μg/cm2/h, respectively. These values were found to be
significantly (P<0.05) higher compared with those of the
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control (8.16±0.62 μg/cm2/h). In addition, the calculated
permeability coefficient values for D-limonene, α-terpineol,
eugenol, and menthol were found to be 4.08±0.27, 3.27±
0.21, 2.73±0.16, and 2.18±0.11 cm/h×10−2, respectively.
Drug-Polymer Compatibility Studies
The DSC thermogram of pure GRN showed a sharp
endothermic peak at ∼300°C, corresponding to the GRN
melting point (thermograms not shown). The appearance of
a sharp endothermic peak is typically attributable to the crys-
talline nature of the materials. The DSC thermogram of
Methocel® E15, Eudragit® RL 100, and Eudragit® RS 100
revealed broad, undefined peaks over a temperature range
of 60–240°C. Such broad endothermic peaks, mainly due to
the dehydration process, are typically observed with
predominantly amorphous polymers.
The FTIR spectral analysis of pure GRN showed the
main peaks at wave numbers 3246, 1647, 1557, 1478, and
1248 cm−1, confirming the purity of the drug (Fig. 3). The
FTIR spectra of the ternary mixtures, GRN:Methocel®
E15:Eudragit® RL 100 (1:1:1) and GRN:Methocel®
E15:Eudragit® RS 100 (1:1:1), showed that the major peaks
of GRN were retained and observed at wave numbers 3245,
1646, 1561, 1471, and 1248 cm−1. The presence of the polymers
did not appear to significantly affect the integrity of the GRN
peaks.
Physicochemical Properties of the Films
The results of the physicochemical properties of the pre-
pared transdermal matrix films are shown in Table II. The
mean weights of the prepared films from all ten formulations
ranged between 55 and 58 mg, and no significant differences
were observed among the formulations evaluated. The chang-
es in the ratio of the incorporated polymers in the formulation
did not appear to have a statistically significant influence on
the weight of the films. The thickness of the prepared films
ranged between 92 and 107 μm. The film thickness appeared
to decrease with decreasing ratio of the Methocel®
E15:Eudragit® polymer in the formulations. These results
are in agreement with those reported previously (31,32). The
results of the flatness study showed that the formulation films
had a negligible change in the length along the longitudinally
cut edges, indicating a near 100% flatness. The films from all
tested formulations appeared to have a smooth, flat surface,
without any visible signs of constriction.
The results of the content uniformity assay of the pre-
pared films are shown in Table II. The GRN content of the
films from different formulations, as obtained from the HPLC
assay, ranged from 98 to 100% w/w of the theoretical concen-
tration. The drug content was found to be statistically similar
across different formulations. The results indicated that the
process employed to prepare films in this study was robust and
capable of producing films without a significant variation. The
folding endurance test results (Table II) showed that the films
prepared from all formulations endured at least 250 strokes of
folding/unfolding at the same location before revealing any
signs of cracking/breaking. These results were found to be
higher than those reported in the literature for similar formu-
lations (17). These results demonstrated the sturdiness of the
films in maintaining their integrity with general skin folding
when applied.
The moisture content of the prepared films from all the
formulations at ambient conditions ranged between 2 and 7%
w/w. The composition of Methocel® E15 in the formulations
was found to influence the moisture content of the films
(Fig. 4a, b). The moisture content increased in a linear
manner with increasing levels of Methocel® E15 for
formulations containing Eudragit® RL 100 (R2=0.9787) or
Eudragit® RS 100 (R2=0.9807). The moisture content among
the formulations containing similar concentrations of either
Eudragit® RL 100 or Eudragit® RS 100 was not found to be
significantly different.
The results of the moisture uptake by the prepared films
at elevated conditions of humidity, i.e., 60% RH, 75% RH,
and 90% RH, are shown in Fig. 5a, b. Similar to the moisture
content results, the moisture uptake by the prepared
Fig. 2. Effect of penetration enhancers on the permeation of GRN. All values are mean±SD
(n=3). *P<0.01, compared to control
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formulation films appeared to depend on the amount of
Methocel® E15 in the formulations. For the formulations
containing Eudragit® RL 100 (Fig. 5a), the moisture uptake
increased linearly with increasing Methocel® E15 at 60% RH
(R2=0.9568), 75% RH (R2=0.9989), and 90% RH (R2=
0.9982). Similarly, for the formulations containing Eudragit®
RS 100 (Fig. 5b), the moisture uptake increased linearly with
increasing Methocel® E15 at 60% RH (R2=0.9485), 75% RH
(R2=0.992), and 90% RH (R2=0.9992). As observed with
moisture content results, the moisture uptake among the
formulations containing similar concentrations of either
Eudragit® RL 100 or Eudragit® RS 100 was not found to be
significantly different.
The water vapor transmission rates (WVTR) in the pre-
pared films were found to range between 0.09 and 0.56 mg/
cm2/h. These results were in agreement with those reported
Fig. 3. FTIR analysis of the drug and the polymers. a Granisetron, b granisetron:Methocel® E15:Eudragit® RL 100 (1:1:1), and c
granisetron:Methocel® E15:Eudragit® RS 100 (1:1:1)
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previously (21,33). Similar to the results obtained from the
moisture content and moisture uptake studies, the WVTR of
the prepared films appeared to correlate linearly with
Methocel® E15 levels in the formulations. For the
formulations containing Eudragit® RL 100 (Fig. 6a), the
WVTR increased linearly with increasing Methocel® E15 at
60% RH (R2=0.8542), 75% RH (R2=0.9991), and 90% RH
(R2=0.9822). Similarly, for the formulations containing
Eudragit® RS 100 (Fig. 6b), the moisture uptake increased
linearly with increasing Methocel® E15 at 60% RH (R2=
0.9454), 75% RH (R2=0.9914), and 90% RH (R2=0.9904).
In Vitro Drug Release
The results of the in vitro drug release from transdermal
films are shown in Fig. 7a, b and Table III. Figure 7a shows the
influence of the ratio of Methocel® E15 and Eudragit® RL 100
on the release of GRN from the prepared transdermal films. It
was observed that the formulation F1 (with the highest ratio of
Methocel® E15:Eudragit® RL 100) exhibited the highest
cumulative amount of GRN released (Table III). For the
subsequent formulations, i.e., F2 to F5, the release of GRN
was found to be progressively slower. Similar results were
Table II. Physicochemical Properties of GRN Films
Formulation Weight (mg) Thickness (μm)
Tensile strength
(kg/mm2) Elongation (%)
Folding
endurance
(no. of strokes) Drug content (%) Flatness
F1 56.21 (4.92) 107 (3.02) 11.01 (0.59) 62.50 (1.09) 257.12 (3.68) 99.47 (0.26) 100.08 (0.12)
F2 55.18 (5.09) 104 (2.54) 10.43 (0.47) 60.09 (1.95) 263.47 (4.98) 99.87 (0.35) 100.14 (0.09)
F3 58.03 (3.12) 99 (2.19) 11.73 (0.82) 61.82 (1.30) 252.41 (3.64) 99.42 (0.50) 99.98 (0.17)
F4 56.47 (3.69) 95 (2.71) 9.57 (0.62) 59.07 (2.00) 255.28 (4.10) 98.89 (0.31) 100.02 (0.16)
F5 56.08 (4.79) 92 (2.59) 10.68 (0.66) 64.13 (1.83) 254.09 (3.83) 100.23 (0.54) 100.16 (0.13)
F6 57.41 (3.28) 106 (3.18) 10.64 (0.78) 62.24 (1.30) 259.28 (4.10) 99.32 (0.52) 99.95 (0.11)
F7 55.20 (4.64) 104 (2.55) 10.85 (0.92) 61.85 (1.88) 253.27 (4.80) 99.73 (0.46) 100.04 (0.16)
F8 57.18 (3.19) 98 (2.41) 11.81 (0.68) 63.04 (1.70) 253.14 (3.99) 99.05 (0.53) 100.11 (0.15)
F9 58.14 (3.20) 96 (2.67) 10.22 (0.49) 63.54 (1.05) 251.27 (4.53) 98.94 (0.57) 99.93 (0.10)
F10 57.16 (3.33) 93 (2.04) 10.69 (0.78) 63.26 (1.83) 251.40 (3.87) 98.91 (0.47) 100.02 (0.15)
All values are expressed as mean (standard deviation), n=3
Fig. 4. The effect of Methocel® E15 levels on the moisture content
(%) of the prepared films. a Formulations containing Eudragit® RL
100. b Formulations containing Eudragit® RS 100
Fig. 5. The effect of Methocel® E15 levels on the moisture uptake
(%) of the prepared films. a Formulations containing Eudragit® RL
100. b Formulations containing Eudragit® RS 100
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observed with formulations containing Eudragit® RS 100
(Fig. 7b). The formulation F6 (with the highest ratio of
Methocel® E15:Eudragit® RS 100) exhibited the highest
cumulative amount of GRN released, and for the subsequent
formulations, i.e., F7 to F10, the release of GRN was found be
progressively slower. Thus, compared with the control, the
GRN release appeared to be significantly influenced by the
ratio of Methocel® E15 and Eudragit® polymers. The
enhancement of drug release in the presence of a
hydrophilic component to an insoluble film former has been
reported earlier (34).
Ex Vivo Drug Permeation
The results of the ex vivo drug permeation studies (across
the excised rat skin) from transdermal films are shown in
Fig. 8a, b and Table III. Similar to the results obtained from
the in vitro drug release studies, it was observed that the
formulation F1 (with the highest ratio of Methocel®
E15:Eudragit® RL 100) exhibited the highest cumulative
amount of GRN permeated (Table III). For the subsequent
formulations, i.e., F2 to F5, the permeation of GRN was found
to be progressively slower (Fig. 8a). Similar results were ob-
served with formulations containing Eudragit® RS 100
(Fig. 8b). The formulation F6 (with the highest ratio of
Methocel® E15:Eudragit® RS 100) exhibited the highest
cumulative amount of GRN permeated, and for the
subsequent formulations, i.e., F7 to F10, the permeation of
GRN was found be progressively slower. Thus, GRN
permeation through the rat skin also appeared to be
influenced by the ratio of Methocel® E15 and Eudragit®
polymers.
Transdermal Flux, Permeation Coefficient, and Enhancement
Ratio
The results of the calculated steady-state transdermal flux
values (Jss) are shown in Fig. 9a, b and Table III. The Jss values
were found to increase in a linear manner with increasing
levels of Methocel® E15 in the formulations containing
Eudragit® RL 100 (R2=0.9868) (Fig. 9a) or Eudragit® RS
100 (R2=0.9915) (Fig. 9b). The Jss values among the
formulations containing similar concentrations of either
Eudragit® RL 100 or Eudragit® RS 100 were not found to
be significantly different.
Similar trends were observed in the calculated permeabil-
ity coefficient and the enhancement ratio results for the for-
mulations (Fig. 10a, b and Table III). For the formulations
containing Eudragit® RL 100, the permeability coefficient
(R2=0.9229) and the enhancement ratio (R2=0.9864) values
Fig. 6. The effect of Methocel® E15 levels on the water vapor
transmission rate of the films. a Formulations containing Eudragit®
RL 100. b Formulations containing Eudragit® RS 100
Fig. 7. The in vitro release of GRN from transdermal films. a Formu-
lations containing Eudragit® RL 100. b Formulations containing
Eudragit® RS 100 (n=3)
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appeared to vary linearly as a function of Methocel® E15
composition.
Similarly, for the formulations containing Eudragit® RL
100, increasing levels of Methocel® E15 resulted in a linear
increase in the permeability coefficient (R2=0.9139) and the
enhancement ratio (R2=0.9915) values.
DISCUSSION
Terpenes are known to function as permeation enhancers
when incorporated in transdermal formulations (35). In the
current study, the comparative permeation-enhancing efficien-
cy of four terpenes, i.e., D-limonene, α-terpineol, eugenol, and
menthol, was evaluated. The hydrocarbon- or non-polar-
group-containing terpenes such as limonene typically provide
a better penetration-enhancing effect for the lipophilic drugs,
Table III. The In Vitro Drug Release, Ex Vivo Skin Permeation, Transdermal Flux, Permeability Coefficient, and Enhancement Ratio of GRN
Films
Formulation Q24 (μg/cm
2)a Q24 (μg/cm
2)b Transdermal flux (Jss) Permeability coefficient (Kp
d) Enhancement ratio (ER)
F1 1297.28 (103.2) 1200.16 (115.6) 42.05 (3.71) 1.20 (0.09) 1.62 (0.13)
F2 1060.32 (97.7) 1025.44 (99.2) 38.83 (3.52) 1.10 (0.08) 1.59 (0.10)
F3 964.96 (89.9) 950.72 (93.2) 35.19 (3.28) 1.00 (0.09) 1.45 (0.09)
F4 895.20 (82.7) 802.08 (85.6) 32.65 (2.51) 0.93 (0.08) 1.42 (0.09)
F5 770.24 (68.6) 688.96 (63.3) 27.87 (2.25) 0.79 (0.07) 1.32 (0.09)
F6 1174.72 (111.5) 1053.44 (99.2) 40.35 (3.49) 1.15 (0.09) 1.54 (0.12)
F7 927.36 (83.6) 881.44 (82.2) 35.77 (3.29) 1.02 (0.08) 1.52 (0.13)
F8 856.64 (81.2) 793.12 (72.9) 32.90 (2.72) 0.94 (0.07) 1.45 (0.10)
F9 721.44 (68.6) 643.36 (56.8) 30.69 (2.58) 0.87 (0.08) 1.39 (0.10)
F10 615.84 (53.4) 557.92 (51.0) 23.95 (2.11) 0.68 (0.05) 1.26 (0.107)
All values are expressed as mean (SD), n=3
aCumulative amount of drug released at the end of 24 h
bCumulative amount of drug permeated at the end of 24 h
Fig. 8. The ex vivo permeation of GRN from transdermal films. a
Formulations containing Eudragit® RL 100. b Formulations
containing Eudragit® RS 100 (n=3)
Fig. 9. Transdermal flux of GRN from the film formulations. a For-
mulations containing Eudragit® RL 100. b Formulations containing
Eudragit® RS 100
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compared with the polar terpenes. D-Limonene is previously
reported to be effective in enhancing the transport of lipophil-
ic molecules such as indomethacin, midazolam, and estradiol
(36). D-Limonene is a hydrophobic terpene, lacking a hydrox-
yl group (log P 4.58±0.23), and the mechanism of its
permeation-enhancing effects is thought to be due to an in-
crease in the partitioning of the drug molecules into the lipid
bilayer of the stratum corneum (37). Based on the results
obtained from the GRN permeation, the calculated transder-
mal flux, and the permeation coefficient values, D-limonene
was identified as the best permeation enhancer among the
terpenes evaluated. D-Limonene was thus selected to be in-
corporated into the formulations prepared to further investi-
gate the influence of other formulation variables on the
functionality of the transdermal films.
The DSC ana ly s i s o f the te rna ry mix tu re s ,
GRN:Methocel® E15:Eudragit® RL 100 (1:1:1) and
GRN:Methocel® E15:Eudragit® RS 100 (1:1:1), revealed a
negligible and a non-significant change in the melting point
of GRN (∼300°C) in the presence of these polymers.
Additionally, the melting signal (endotherm) was clearly
distinguishable in both ternary mixtures. Since no other
endothermic/exothermic event was observed in this region,
any interaction or obvious incompatibility between the drug
and the polymers can be safely excluded. The DSC results
thus indicated the suitability of these polymers to be used in
the transdermal film formulations (19). Similarly, the FTIR
analysis of the ternary mixtures of the drug and the polymers
did not reveal any interferences with the major peaks
associated with GRN. The DSC and FTIR results thus indi-
cated that the drug and polymers are compatible. Methocel®
E15, Eudragit® RL 100, and Eudragit® RS 100 are commonly
used polymers, incorporated in a wide range of controlled/
sustained-release matrix-type transdermal drug delivery sys-
tems due to their compatibility with several drugs (38).
The prepared transdermal films were evaluated for the
physicochemical properties using commonly used, well-
established, and standard methods. The physical characteris-
tics of the films such as weight variation, thickness, and flat-
ness were found to be consistent among the formulations and
within acceptable limits. The moisture content and the mois-
ture uptake values of the prepared films were found to be
dependent on the incorporated hydrophilic polymer ratio. An
increase in the moisture content and moisture uptake by
polymeric films as a function of increasing levels of hydrophil-
ic polymers has been reported earlier (18,31,32,39). A small
amount of moisture in the films is thought to be essential to
maintain the stability and integrity of the films and to prevent
excessive drying (resulting in brittleness and cracking) of the
films (18,39). The water vapor transmission rate (WVTR) is a
parameter commonly used to evaluate the amount of moisture
transmitted through the transdermal films containing hydro-
philic polymers (21,40). The prepared transdermal films
showed predictable and linearly proportional WVTR values
with increasing Methocel® E15 content. Tanwar et al. have
previously reported higher film WVTR values for HPMC-
based films and attributed this to the hydrophilicity of the
polymer incorporated (33).
The physicochemical properties of the drug and the de-
livery system, as well as the physiological and physicochemical
properties of the biological membrane, typically determine the
rate and extent of the drug release from the transdermal films
(41). In an attempt to describe the release kinetics of GRN
from the prepared transdermal films, the results from the
in vitro release studies was fitted to different kinetic models
such as the zero-order release, first-order release, Higuchi,
and Korsmeyer-Peppas release models (42). The cumulative
amount of drug released from the films, when plotted against
the square root of time, exhibited release profiles of the drug
which appeared to follow the Higuchi model, as evidenced by
the range of correlation coefficient values (R2=0.97 to 0.99).
The correlation coefficient values for the zero-order (R2=0.93
to 0.95) and the first-order (R2=0.56 to 0.60) kinetics were
lower than those for the Higuchi kinetics (Table IV).
Korsmeyer et al. used a simple empirical equation (Eq. (11))
to describe the release behavior of molecules from the poly-
mer matrices (16):
Mt
M∞
¼ Ktn ð11Þ
where MtM∞ is the fraction of drug released, K is the rate con-
stant, t is time for the drug release, and n is the diffusional
exponent for drug release. Peppas stated that, regardless of
the mechanism of release, the above equation can describe the
drug release from polymer matrices of various geometries.
The release mechanism is typically indicated by the value of
the diffusional exponent (n). For example, when n=1, the
release can be considered Bzero-order^ (case II transport),
Fig. 10. Permeability coefficient and enhancement ratio of GRN from
transdermal films. Values are mean±SD (n=3)
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and n=0.5 indicates a Fickian diffusion-based release; when
0.5<n<1.0, diffusion and non-Fickian transport may be in-
volved. Lastly, when n>1.0, the apparent mechanism is Bsuper
case II transport.^ The value of n is obtained from the slope of
logMtM∞ vs the log time curve. The n values for the GRN release
obtained using this equation (0.53 to 0.75) indicated that the
main mechanism of GRN release from the prepared films was
general, non-Fickian diffusion. The hydration and subsequent
swelling of the incorporated hydrophilic polymer Methocel®
E15 may possibly explain the observed mechanism of GRN
release.
Overall, the formulations containing Eudragit® RL 100
exhibited GRN release that was higher in rate and extent,
compared with those containing Eudragit® RS 100.
Eudragit® RL 100 contains a higher proportion of the
hydrophilic quaternary ammonium groups compared with
Eudragit® RS 100, which may result in a rapid hydration of
the matrix and subsequent drug release (33). An increase in
the amount and hydrophobicity of the incorporated polymers
is known to slow the drug release rates. In such cases, the
mechanism of the drug release shifts towards polymer
relaxation and matrix erosion (43,44).
A mild burst release of GRN was observed with all
formulations. This may be attributed to the direct exposure
of the matrix films to dissolution media. Due to the hydrophil-
ic nature of the polymer used, the polymeric matrix may form
loose channels within the network, resulting in a rapid release
of the drug present in the surface layers of the film. The
observed initial release may assist in achieving the therapeutic
plasma concentration of the drug in a short time, followed by a
constant release over a longer period of time (43,44). The
initial burst release was observed to be higher in the matrix
film Eudragit® RL 100 polymer compared with Eudragit® RS
100, although this effect was not significant.
The cumulative amount of drug permeated (per square
centimeter of films) through the rat abdominal skin, when
plotted against time, exhibited permeation profiles that ap-
peared to follow Higuchi’s equation as evidenced by the cal-
culated range of correlation coefficient values (R2=0.98 to
0.99). The correlation coefficient values for the first-order
(R2=0.60 to 0.62) and the zero-order (R2=0.96 to 0.98)
kinetics were found to be relatively lower than those
obtained with the Higuchi kinetics (Table V). As described
earlier by Rao et al., the initial rapid dissolution of the hydro-
philic polymer occurs when the film is in contact with the
hydrated skin, resulting in the accumulation of high amounts
of drug in the skin surface, thus leading to saturation of the
skin with drug molecules (45).
The calculated values of transdermal flux, permeation
coefficient, and the enhancement ratio for the prepared films
were found to increase linearly with increasing levels of the
hydrophilic polymer, i.e., Methocel® E15 in the formulation.
These parameters are commonly used to evaluate the
functionality of transdermal preparations and to provide a
better understanding of the mechanisms of transdermal
absorption of drugs (12,23). Hydrophilic-matrix-based films
in the presence of permeation enhancers are known to dem-
onstrate higher values of transdermal flux, permeation coeffi-
cient, and enhancement ratio.
CONCLUSIONS
The influence of formulation variables such as perme-
ation enhancers (terpenes), hydrophilic matrix former
(Methocel® E15), and film formers (Eudragit® RL 100
and Eudragit® RS 100) on the quality and functionality
of a transdermal film formulation was evaluated.
Consistent with the previous findings, D-limonene was
found to be the most efficient permeation enhancer
among the tested terpenes. The composition ratio of the
hydrophilic matrix former and the film-forming polymers
influenced the physicochemical and functional characteris-
tics of the prepared films. A transdermal film formulation,
having the required quality and performance attributes,
can be optimally designed by the use of an appropriate
type and amount of the above ingredients. The study
emphasizes the importance of the rational selection of a
combination of excipients to achieve targeted dosage form
functionality.
REFERENCES
1. Prausnitz MR, Mitragotri S, Langer R. Current status and future
potential of transdermal drug delivery. Nat Rev Drug Discov.
2004;3(2):115–24.
2. Ruby PK, Pathak SM, Aggarwal D. Critical attributes of trans-
dermal drug delivery system (TDDS)—a generic product devel-
opment review. Drug Dev Ind Pharm. 2014;40(11):1421–8.
3. Thomas BJ, Finnin BC. The transdermal revolution. Drug Discov
Today. 2004;9(16):697–703.
Table IV. In Vitro Release Kinetics of GRN Films
Formulation
Zero
order
(R2)
First
order
(R2)
Higuchi
model
(R2)
Korsmeyer-Peppas
model (n)
F1 0.9312 0.6047 0.9907 0.5360
F2 0.9456 0.6066 0.9824 0.5428
F3 0.9404 0.5719 0.9724 0.6206
F4 0.9376 0.5937 0.9849 0.6029
F5 0.9564 0.5738 0.9857 0.6619
F6 0.9439 0.5904 0.9749 0.5968
F7 0.9579 0.5637 0.9726 0.6315
F8 0.9438 0.5793 0.9852 0.5726
F9 0.9379 0.5632 0.9705 0.7104
F10 0.9468 0.5937 0.9747 0.7572
Table V. Ex Vivo Permeation Kinetics of GRN Films
Formulation
Zero
order
(R2)
First
order
(R2)
Higuchi
model
(R2)
Korsmeyer-
Peppas model
(n)
F1 0.9679 0.6108 0.9907 0.5200
F2 0.9745 0.6087 0.9921 0.5790
F3 0.9684 0.6147 0.9903 0.5919
F4 0.9803 0.6124 0.9865 0.5606
F5 0.9748 0.6185 0.9912 0.6185
F6 0.9684 0.6073 0.9906 0.5321
F7 0.9843 0.6073 0.9858 0.6097
F8 0.9642 0.6138 0.9931 0.6034
F9 0.9753 0.6218 0.9914 0.6113
F10 0.9734 0.6135 0.9925 0.7301
1355Influence of Component Excipients on Transdermal Films
4. Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P,
Stinchcomb AL. Challenges and opportunities in dermal/
transdermal delivery. Ther Deliv. 2010;1(1):109–31.
5. Prausnitz MR, Langer R. Transdermal drug delivery. Nat
Biotechnol. 2008;26(11):1261–8.
6. Zadymova NM. Colloidochemical aspects of transdermal drug
delivery (review). Colloid J. 2013;75(5):491–503.
7. Vavrova K, Zbytovska J, Hrabalek A. Amphiphilic transdermal
permeation enhancers: structure-activity relationships. Curr Med
Chem. 2005;12(19):2273–91.
8. Williams AC, Barry BW. Essential oils as novel human skin
penetration enhancers. Int J Pharm. 1989;57(2):R7–9.
9. Patil U, Saraogi R. Natural products as potential drug permeation
enhancer in transdermal drug delivery system. Arch Dermatol
Res. 2014;306(5):419–26.
10. Karande P, Jain A, Ergun K, Kispersky V, Mitragotri S. Design
principles of chemical penetration enhancers for transdermal
drug delivery. Proc Natl Acad Sci U S A. 2005;102(13):4688–93.
11. Parikh D, Ghosh T. Feasibility of transdermal delivery of fluox-
etine. AAPS PharmSciTech. 2005;6(2):E144–9.
12. Williams AC, Barry BW. Terpenes and the lipid protein
partitioning theory of skin penetration enhancement. Pharm
Res. 1991;8(1):17–24.
13. Gao S, Singh J. In vitro percutaneous absorption enhancement of
a lipophilic drug tamoxifen by terpenes. J Control Release.
1998;51(2–3):193–9.
14. Herman A, Herman AP. Essential oils and their constituents as
skin penetration enhancer for transdermal drug delivery: a re-
view. J Pharm Pharmacol. 2015;67(4):473–85.
15. Zhao KD, Singh J. In vitro percutaneous absorption enhance-
ment of propranolol hydrochloride through porcine epidermis by
terpenes/ethanol. J Control Release. 1999;62(3):359–66.
16. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mech-
anisms of potassium chloride release from compressed, hydro-
philic, polymeric matrices: effect of entrapped air. J Pharm Sci.
1983;72(10):1189–91.
17. Kusum Devi V, Saisivam S, Maria GR, Deepti PU. Design and
evaluation of matrix diffusion controlled transdermal patches of ve-
rapamil hydrochloride. Drug Dev Ind Pharm. 2003;29(5):495–503.
18. Mutalik S, Udupa N. Glibenclamide transdermal patches: physi-
cochemical, pharmacodynamic, and pharmacokinetic evaluations.
J Pharm Sci. 2004;93(6):1577–94.
19. Chandak AR, Verma PRP. Development and evaluation of
HPMC based matrices for transdermal patches of tramadol. Clin
Res Regul Aff. 2008;25(1):13–30.
20. Kshirsagar SJ, Bhalekar MR, Mohapatra SK. Development and
evaluation of carvedilol-loaded transdermal drug delivery system:
in-vitro and in-vivo characterization study. Drug Dev Ind Pharm.
2012;38(12):1530–7.
21. Madan JR, Argade NS, Dua K. Formulation and evaluation of
transdermal patches of donepezil. Recent pat drug delivery for-
mulation. 2014.
22. Hayton WL, Chen T. Correction of perfusate concentration for
sample removal. J Pharm Sci. 1982;71(7):820–1.
23. Barry BW. Mode of action of penetration enhancers in human
skin. J Control Release. 1987;6(1):85–97.
24. Riviere A. Dose finding study of granisetron in patients receiving
high-dose cisplatin chemotherapy. The Granisetron Study Group.
Br J Cancer. 1994;69(5):967–71.
25. Yener G, Uuml LG, Uuml, Uuml, Ner M, et al. Design of
meloxicam and lornoxicam transdermal patches: preparation,
physical characterization, ex vivo and in vivo studies. Chem
Pharm Bull. 2010;58(11):1466–73.
26. Khana R, Agarwal SP, Ahuja A. Preparation and evaluation of
muco-adhesive buccal films of clotrimazole for oral candida in-
fections. Indian J Pharm Sci. 1997;59(6):299–305.
27. Pinguet F, Bressolle F, Martel P, Salabert D, Astre C. High-
performance liquid chromatographic determination of
granisetron in human plasma. J Chromatogr B Biomed Appl.
1996;675(1):99–105.
28. Aggarwal G, Dhawan S, Hari Kumar SL. Formulation, in vitro
and in vivo evaluation of transdermal patches containing risper-
idone. Drug Dev Ind Pharm. 2013;39(1):39–50.
29. Greenspan L. Humidity fixed points of binary saturated aqueous
solutions. J Res Nat Bur Stand Sect A. 1977;81A(1):89–96.
30. Suwanpidokkul N, Thongnopnua P, Umprayn K. Transdermal
delivery of zidovudine (AZT): the effects of vehicles, enhancers,
and polymer membranes on permeation across cadaver pig skin.
AAPS PharmSciTech. 2004;5(3):82–9.
31. Mamatha T, Venkateswara RJ, Mukkanti K, Ramesh G. Trans-
d e rm a l d r u g d e l i v e r y s y s t em f o r a t om o x e t i n e
hydrochloride—in vitro and ex vivo evaluation. Curr Trends
Biotechnol Pharm. 2009;3(2):188–96.
32. Tirunagari M, Jangala VR, Khagga M, Gannu R. Transdermal
therapeutic system of isradipine: effect of hydrophilic and hydro-
phobic matrix on in vitro and ex vivo characteristics. Arch Pharm
Res. 2010;33(7):1025–33.
33. Tanwar YS, Chauhan CS, Sharma A. Development and evalua-
tion of carvedilol transdermal patches. Acta Pharm (Zagreb,
Croatia). 2007;57:151–9.
34. Bodmeier R, Paeratakul O. Drug release from laminated poly-
meric films prepared from aqueous latexes. J Pharm Sci.
1990;79(1):32–6.
35. Aqil M, Ahad A, Sultana V, Ali A. Status of terpenes as skin
penetration enhancers. Drug Discov Today. 2007;12(23–
24):1061–7.
36. Yang Z, Teng Y, Wang H, Hou H. Enhancement of skin perme-
ation of bufalin by limonene via reservoir type transdermal patch:
formulation design and biopharmaceutical evaluation. Int J
Pharm. 2013;447(1–2):231–40.
37. Krishnaiah YS, Bhaskar P, Satyanarayana V. In vitro percutane-
ous permeability enhancement of nimodipine by limonene across
the excised rat abdominal skin. Pharmazie. 2005;59:942–7.
38. Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceu-
tical excipients. Sixth ed. Rowe RC, Sheskey PJ, Quinn ME,
editors. Washington, DC: London; Greyslake, IL : Pharma-
ceutical Press; Washington, DC : American Pharmacists As-
sociation, 2009; 2009.
39. Ubaidulla U, Reddy MVS, Ruckmani K, Ahmad FJ, Khar RK.
Transdermal therapeutic system of carvedilol: effect of hydrophil-
ic and hydrophobic matrix on in vitro and in vivo characteristics.
AAPS PharmSciTech. 2007;8(1):E13–20.
40. Madishetti SK, Palem CR, Gannu R, Thatipamula RP, Panakanti
PK, Yamsani MR. Development of domperidone bilayered ma-
trix type transdermal patches: physicochemical, in vitro and
ex vivo characterization. DARU J Pharm Sci. 2010;18(3):221–9.
41. Chien YW. Development of transdermal drug delivery systems.
Drug Dev Ind Pharm. 1987;13(4/5):589.
42. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution
profiles. Eur J Pharm Sci. 2001;13(2):123–33.
43. Chandak AR, Verma PRP. Design and development of hydroxy-
propyl methycellulose (HPMC) based polymeric films of metho-
trexate: physicochemical and pharmacokinetic evaluations.
Yakugaku Zasshi. 2008;128:1057–66.
44. Prasad Verma PR, Chandak AR. Development of matrix con-
trolled transdermal delivery systems of pentazocine: in vitro/in
vivo performance. Acta Pharm (Zagreb, Croatia). 2009;59:171–
86.
45. Rao PR, Diwan PV. Formulation and in vitro evaluation of
polymeric films of diltiazem hydrochloride and indomethacin
for transdermal administration. Drug Dev Ind Pharm.
1998;24(4):327–36.
1356 Saoji et al.
